Two groups have published their research findings regarding the use of gene therapy in the prevention and treatment of prostate cancer.
One group, led by Dr. T. C. Thompson, used an adenoviral vector capable of efficient transduction and expression of a novel p53 target gene RTVP-1 (AdRTVP-1), together with a highly metastatic mouse prostate cancer cell line (178-2 BMA), to prepare a vaccine (Cancer Gene Therapy, Vol. 13, pp. 658–663, 2006).
The second group, headed by Dr. Z. Dong, studied the efficacy and mechanisms of adenoviral vector-mediated interferon (IFN)- gene therapy in inhibiting orthotopic growth of human prostate cancer in immune-competent mice, producing data indicating that IFN-gene therapy could be an effective alternative for the treatment of locally advanced prostate cancer and suggesting an obligatory role of Nitric Oxide in IFN- antitumoral effects in vivo (Cancer Gene Therapy, Vol. 13, pp. 676–685, 2006).
Dr. T. C. Thompson, Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, Suite 2100, Houston, TX 77030, USA.
Dr. Z. Dong, Department of Internal Medicine, Hematology-Oncology Division, University of Cincinnati College of Medicine, 3125 Eden Avenue, Rm 1308, Cincinnati, OH 45267, USA.
Abstracts available online:
(C) Cancer Gene Therapy.
Posted by: Tressie Dalaya
Message posted by: Trevor M. D'Souza